Prosecution Insights
Last updated: May 29, 2026
Application No. 18/035,176

METHOD FOR STABILIZING AN ORGANIC MATERIAL USING A STABILIZER MIXTURE

Non-Final OA §112
Filed
May 03, 2023
Priority
Nov 03, 2020 — EU 20205384.9 +1 more
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
830 granted / 1021 resolved
+21.3% vs TC avg
Moderate +9% lift
Without
With
+9.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
59 currently pending
Career history
1077
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
22.3%
-17.7% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
32.6%
-7.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1021 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s election without traverse of a composition comprising a compound of formula (I), a UV absorber containing a benzotriazole ring, and metal hydroxide in the reply filed on 2026 January 13 is acknowledged. A search has been extended to a composition comprising one, a compound of formula (I), two, a UV absorber broadly, and three, a metal, or inorganic, oxide. Information Disclosure Statement The information disclosure statements (IDS) submitted on 2025 May 15, 2025 December 25, 2026 January 20 and March 19 were submitted in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are considered by the examiner. Claim Objections Claims 7, 13-18, and 20 are objected to because of the following informalities: the image of a compound of formula (A-1) is illegible due the alkyl groups being hard to read. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim(s) 1-6 and 8-12 is/are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph due to lack of written description. The MPEP states that the purpose of the written description requirement is to ensure that the inventor had possession, as of the filing date of the application, of the specific subject matter later claimed by him. The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the Application. These include “level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would lead one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient.” MPEP § 2163. While all of the factors have been considered, a sufficient amount for a prima facie case are discussed below. In the instant case, claims 1-6 and 8-12 are drawn to a method of stabilizing an organic material by reducing degradation induced by a chlorine-containing compound having a chlorine content in the range of 100-600 ppm, wherein the method comprises incorporating the organic material a stabiliser mixture comprising components (i), (ii), and (iii). Component (i) is selected from different agents. Component (ii) is a UV absorber and component (iii) is a metal, or inorganic, hydroxide. Level of skill and knowledge in the art: HUGLIN (Chimia, 2016, 70 (7/8), 496-501) describes UV absorbers with the genus below (page 497, figure 1). PNG media_image1.png 282 272 media_image1.png Greyscale (2) Partial structure: Applicants discuss various agrochemical or bleaching chlorine-containing compounds (specification page 36, line 27 to page 37, line 4). (3) Physical and/or chemical properties and (4) Functional characteristics: Various compositions are described (pages 73-74, tables 1 and 2). (5) Method of making the claimed invention: A method of making the stabiliser composition is described (page 72, lines 13-24). The MPEP states that written description for a genus can be achieved by a representative number of species within a broad generic. It is unquestionable that claim(s) 1-6 and 8-12 is/are broad and generic, with respect to all possible compounds encompassed by the claims. The possible structural variations are limitless to any method of reducing degradation induced by a chlorine-containing compound having a chlorine content in the range of 100-600 ppm, wherein the method comprises incorporating the organic material a stabiliser mixture comprising components (i), (ii), and (iii). Component (i) is selected from different agents. Component (ii) is a UV absorber and component (iii) is a metal, or inorganic, hydroxide. Although the claims may recite some functional characteristics, the claims lack written description because there is no disclosure of a correlation between function and structure of the compounds beyond those compounds specifically disclosed in the examples in the specification. Moreover, the specification lack sufficient variety of species to reflect this variance in the genus. While having written description of compounds identified in the specification tables and/or examples, the specification does not provide sufficient descriptive support for the myriad of compounds embraced by the claims. The description requirement of the patent statue requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See In re Wilder, 736, F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming rejection because the specification does “little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate.”) Accordingly, it is deemed that the specification fails to provide adequate written description for the genus of the claims and does not reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the entire scope of the claimed invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-18 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claims 1-6 and 8-12, what is the parts per million concentration of chlorine based on? MARCZEWSKI (Extension Bulletin E-1641, 1982, pages 1 and 2) describes that parts per million is defined as 1 mg in a kilogram (page 1). The metes and bounds of the chlorine concentration is indefinite the denominator, kilograms, is unclear. Is the denominator based on the organic material or another substance? In the specification, a sodium hypochlorite, NAClO to water solution in a ratio of 1:4 is specified (page 72, lines 28 and 29). This teaching does not limit the claims. Due to the unclear definition of what a kilogram is based on for purposes of calculating parts per million, this limitation is unclear. Claims 1-8 and 10-18 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being incomplete for omitting essential structural cooperative relationships of elements, such omission amounting to a gap between the necessary structural connections. See MPEP § 2172.01. The omitted structural cooperative relationships are: the structural metes and bounds of a UV absorber. Applicants discuss specific UV absorbers (page 37, line 6 to page 38, line 24) which do not limit the claims. HUGLIN (Chimia, 2016, 70 (7/8), 496-501) describes UV absorbers with the genus below (page 497, figure 1). PNG media_image1.png 282 272 media_image1.png Greyscale Conclusion Claims 1-18 and 20 are not allowable. The following is a statement of reasons for the indication of allowable subject matter: TANG (CN 106397838, published 2015 February 15) describes a composition containing aluminum hydroxide, a benzotriazole UV absorbing agent, and a compound containing a triazine connected to an N-piperidine group. This composition does not anticipate or render obvious a method of claim 1 or a composition of claim 7 for the following reasons: the composition is used in a flame retardant composition; and the triazine polymer is not the same as a compound formula (A-1). PNG media_image2.png 218 334 media_image2.png Greyscale PNG media_image3.png 260 404 media_image3.png Greyscale Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

May 03, 2023
Application Filed
May 06, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630589
COMPOUNDS FOR USE IN VIRAL INFECTIONS
3y 8m to grant Granted May 19, 2026
Patent 12624080
Multi-receptor (GLP-1 receptor, GIP receptor, and Gcg receptor) agonist protein
3y 11m to grant Granted May 12, 2026
Patent 12595235
PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES
3y 6m to grant Granted Apr 07, 2026
Patent 12595265
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
2y 11m to grant Granted Apr 07, 2026
Patent 12588410
ORGANIC ELECTROLUMINESCENT MATERIAL AND METHOD PREPARING THE SAME
3y 3m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+9.0%)
2y 11m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1021 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month